{"id":15372,"date":"2018-06-20T16:05:45","date_gmt":"2018-06-20T16:05:45","guid":{"rendered":"http:\/\/touchoncology.com\/media_gallery\/martin-hutchings-eha-2018-echelon-1-trial-and-chemotherapy-regimens-in-hodgkins-lymphoma\/"},"modified":"2019-03-08T10:30:11","modified_gmt":"2019-03-08T10:30:11","slug":"martin-hutchings-eha-2018-echelon-1-trial-and-chemotherapy-regimens-in-hodgkins-lymphoma","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/lymphoma\/conference-hub\/martin-hutchings-eha-2018-echelon-1-trial-and-chemotherapy-regimens-in-hodgkins-lymphoma\/","title":{"rendered":"Martin Hutchings, EHA 2018 \u2013 ECHELON-1 trial and chemotherapy regimens in Hodgkin\u2019s lymphoma"},"content":{"rendered":"<\/p>\n<p>Martin Hutchings from Copenhagen University Hospital discusses the ECHELON-1 trial and treatment strategies in Hodgkin&#8217;s lymphoma.<\/p>\n<\/p>\n<p>1.  What are the limitations of current ABVD chemotherapy regimes for advanced Hodgkin\u2019s lymphoma? (0:10)<\/p>\n<p>2.  Could you tell us a little about the ECHELON-1 study and its findings? (1:04)<\/p>\n<p>3.  What toxicities were associated with the A+AVD regimen? (2:11)<\/p>\n<p>4.  What patients are most likely to respond to this approach? (4:46)<\/p>\n<p>5.  What future studies are planned? (6:05)<\/p>\n<\/p>\n<p><b>Speaker disclosures:<\/b> Martin Hutchings has nothing to disclose in relation to this video interview.<\/p>\n<p><b><i>Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14\u201317 2018<\/i><\/b><\/p>\n<p><i>A+AVD = brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine<\/p>\n<p><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Martin Hutchings from Copenhagen University Hospital discusses the ECHELON-1 trial and treatment strategies in Hodgkin&#8217;s lymphoma. 1. What are the limitations of current ABVD chemotherapy regimes for advanced Hodgkin\u2019s lymphoma? (0:10) 2. Could you tell us a little about the ECHELON-1 study and its findings? (1:04) 3. What toxicities were associated with the A+AVD regimen? [&hellip;]<\/p>\n","protected":false},"featured_media":15373,"template":"","class_list":["post-15372","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-lymphoma","video_categories-eha-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/15372"}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":0,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/15372\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/15373"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=15372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}